Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow EBR Systems, Inc.

Get SEC filing alerts via email and in your feed for EBR Systems, Inc.

EBRCZ

EBR Systems, Inc.

About EBR Systems, Inc.

EBR Systems, Inc. develops leadless cardiac pacing technology, including the WiSE CRT System, for heart rhythm correction. Its innovative implantable devices deliver ultrasound-based left-ventricle pacing without leads, targeting patients with heart failure unresponsive to conventional therapies. The company focuses on regulatory approval, clinical trials, and commercialization in the U.S. and international markets, emphasizing safety, efficacy, and intellectual property protection in the medical device sector.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from EBR Systems, Inc.

1
1
EBR Systems, Inc. EBR Systems Reports $17.1 Million Net Loss in Q1 2026, Revenue from WiSE CRT System

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
EBR Systems, Inc. EBR Systems Reports $48.8 Million Net Loss and $1.6 Million Revenue for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
EBR Systems, Inc. EBR Systems Reports Revenue Growth Following FDA Approval, Despite Increased Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
EBR Systems, Inc. EBR Systems Reports $169,704 Revenue in Q2 2025, Net Loss Increases

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
EBR Systems, Inc. EBR Systems Reports Net Loss of $10.1M in Q3 2024, Sees Increased Expenses and Decreased Cash Reserves

Via official filing (AI summary) | over 1 year ago | 0 comments